Free public records show Shanghai Minwei Biotechnology Co., Ltd in 4 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Shanghai Minwei Biotechnology Co., Ltd or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
13 active studies led by Shanghai Minwei Biotechnology Co., Ltd, of 21 in all
Source: ClinicalTrials.gov, Studies with Shanghai Minwei Biotechnology Co., Ltd (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Shanghai Minwei Biotechnology Co., Ltd leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Shanghai Minwei Biotechnology Co., Ltd or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Shanghai Minwei Biotechnology Co., Ltd: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Shanghai Minwei Biotechnology Co., Ltd is in.
Stories on the topics Shanghai Minwei Biotechnology Co., Ltd works in.
An IOC study found 14.8% of supplements tested contained undeclared steroids. Sports nutrition now sells to…
Read
2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack…
Read
Creatine is one of the most studied supplements in sport. Now it is reaching everyday buyers. What the…
ReadSearch all reports for Shanghai Minwei Biotechnology Co., Ltd All companies